Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
OHSU Knight Cancer Institute
With
Pfizer
PRIMARY OBJECTIVE
I. To determine if COX-2 inhibition with celecoxib significantly increases apoptosis in human adenocarcinoma of the prostate.
SECONDARY OBJECTIVES
I. To determine if COX-2 inhibition with celecoxib reduces levels of Prostaglandin E2 and androgen receptor in fresh tumor tissue collected at prostatectomy
II. To collect pre- and postoperative serum Prostate Specific Antigen (PSA) for exploratory analyses
III. To determine the effect of celecoxib on adverse effects, perioperative surgical complications and post surgery analgesic use
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Histopathologically or cytologically proven adenocarcinoma of the prostate and planned prostatectomy
Age \>= 18
Performance status (ECOG \<= 2)
Hemoglobin \> 10 g/dL (within 4 weeks)
Creatinine \<= 1.5 mg/dL
Signed informed patient consent
You may not be if
Other preoperative or prior treatment directed at prostate cancer
Significant active medical illness which in the opinion of the investigator would preclude protocol treatment
Use of non-steroidal anti-inflammatory agents within seven days of celecoxib treatment
Hypersensitivity to celecoxib
A history of asthma, urticaria, or anaphylaxis precipitated by an NSAID
History of significant upper gastrointestinal bleeding or active peptic ulcer disease
